Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Hematologic Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02192775
What this trial is testing

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

Who this might be right for
Multiple Myeloma
University of Arkansas 2
Testing effectiveness (Phase 2)Looking for participantsNCT04414475
What this trial is testing

Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Who this might be right for
Multiple Myeloma, Refractory
Karyopharm Therapeutics Inc 127
Early research (Phase 1)Study completedNCT00136422
What this trial is testing

Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplasia
Dana-Farber Cancer Institute 30
Large-scale testing (Phase 3)Study completedNCT00002456
What this trial is testing

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma
Fred Hutchinson Cancer Center
Early research (Phase 1)Looking for participantsNCT07225439
What this trial is testing

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more
Paolo Caimi, MD 15
Early research (Phase 1)Looking for participantsNCT07668557
What this trial is testing

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
iCell Gene Therapeutics 18
Testing effectiveness (Phase 2)Looking for participantsNCT07032129
What this trial is testing

Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma Progression+1 more
Essen Biotech 60
Testing effectiveness (Phase 2)Study completedNCT01101880
What this trial is testing

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+8 more
University of Washington 50
Early research (Phase 1)Study completedNCT05548088
What this trial is testing

LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia
Peking University People's Hospital 11
Testing effectiveness (Phase 2)Looking for participantsNCT06542250
What this trial is testing

Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Who this might be right for
B-cell Malignancies
AstraZeneca 174
Testing effectiveness (Phase 2)Ended earlyNCT00522990
What this trial is testing

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myeloid Leukemia+2 more
Astex Pharmaceuticals, Inc. 48
Testing effectiveness (Phase 2)Ended earlyNCT04639024
What this trial is testing

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Myeloproliferative Neoplasm (MDS/MPN)
Gwynn Long, M.D. 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439123
What this trial is testing

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)UnknownNCT04353479
What this trial is testing

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine 29
Testing effectiveness (Phase 2)Ended earlyNCT01534143
What this trial is testing

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
Barbara Ann Karmanos Cancer Institute 1
Testing effectiveness (Phase 2)Looking for participantsNCT06138990
What this trial is testing

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

Who this might be right for
AML, Adult
ETH Zurich 88
Early research (Phase 1)Looking for participantsNCT06737523
What this trial is testing

Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML

Who this might be right for
Acute Myeloid LeukemiaRelapseRefractory AML
The First Affiliated Hospital of Xiamen University 30
Very early researchUnknownNCT03795779
What this trial is testing

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more
iCell Gene Therapeutics 20
Large-scale testing (Phase 3)Study completedNCT03952091
What this trial is testing

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple Myeloma
TJ Biopharma Co., Ltd. 289
Testing effectiveness (Phase 2)Study completedNCT00006013
What this trial is testing

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Fox Chase Cancer Center 21
Next Page